HTG Molecular Diagnostics, Inc. (Formerly Known as High Throughput Genomics, Inc.) Edge System a Finalist for Medical Design Excellence Award

TUCSON, AZ--(Marketwired - April 05, 2013) -

Highlighted Links

HTG Molecular Diagnostics

The Edge System, developed by HTG Molecular Diagnostics, is a finalist in the 15th Annual Medical Design Excellence Awards competition. HTG Molecular Diagnostics is a privately held company specializing in RNA based diagnostics and solutions for translational research. The HTG Edge System is the only automated gene expression platform that delivers affordable, multiplexed results on critical FFPE samples in 24 hours. Developed under strict ISO 13485:2003 standards, the Edge System delivers up to 4,512 data points using less than a single 5µm tissue section. The revolutionary Edge System provides high frozen-to-FFPE correlation and walk-away automation of the patented qNPA technology; eliminating time-consuming and complex qPCR processes of extraction, amplification, and labeling.

TJ Johnson, CEO of HTG Molecular Diagnostics states, "We are extremely proud to have the Edge design recognized as an MDEA finalist. We heard loud and clear from our customers that the market needs a simple and cost effective way to perform RNA testing with fast turnaround. The Edge was designed to fulfill this unmet market need."

The Medical Design Excellence Awards (www.MDEAwards.com) are the industry's premier design awards competition and the only awards program exclusively recognizing contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions improving healthcare delivery and changing traditional medical attitudes or practices, features providing enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so the product meets its clinical objectives.

A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics. Finalists in each of the competition's ten categories were officially announced in the April issue of Medical Device and Diagnostic Industry (www.mddionline.com) magazine. The winners will be announced on June 19, 2013, during a cocktail reception at 4:30 pm at the Marriott Hotel in downtown Philadelphia. The ceremony will be held in conjunction with the 30th MD&M East event (www.MDMEast.com) at the Pennsylvania Convention Center. MDEA-winning products will be honored at the ceremony with Bronze, Silver, or Gold-level awards in each category. One Gold-winning product will be awarded 'Best-in-Show'.

The Medical Design Excellence Awards are underwritten and presented by UBM Canon, the global advanced manufacturing and MedTech authority, and by Medical Device and Diagnostic Industry (MD+DI), the industry's central source for late breaking news, information, and business intelligence. For more information about the Medical Design Excellence Awards, visit www.MDEAwards.com, or e-mail mdea@ubm.com.

ABOUT HTG MOLECULAR DIAGNOSTICS:
HTG Molecular Diagnostics is a privately held company providing products for gene expression profiling, miRNA, and mRNA measurement for translational research. The company's qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels; especially from formalin-fixed, paraffin-embedded (FFPE) tissue. Additional information is available at www.htgmolecular.com.

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: molecular diagnostics translational research FFPE mRNA miRNA gene expression